HEAD AND NECK SQUAMOUS CELL CARCINOMA

This study tested a biosimilar drug called RPH-002, which is a copy of the cancer drug Erbitux, in 118 people with advanced head and neck cancer that could not be removed by surgery. The main goal was to see if the body processes RPH-002 the same way as Erbitux and to check for s…

This Phase 3 trial tested whether adding lenvatinib to pembrolizumab (Keytruda) helps people with recurrent or metastatic head and neck squamous cell carcinoma that has a specific marker (PD-L1). The study enrolled 112 participants and compared the combination against pembrolizum…

This phase 2 trial tested a new approach for people with intermediate-risk HPV-related head and neck cancer. Participants received an HPV-16 vaccine (ISA101b) plus the immunotherapy drug pembrolizumab alongside standard chemoradiation. The goal was to see if this combination coul…

This completed phase II study tested a combination of two drugs—tadalafil (Cialis) and pembrolizumab (Keytruda)—in 7 adults with advanced head and neck cancer that had spread or come back. The goal was to see if the combination was safe and could help control the disease. Because…

This early-stage trial tested a new type of cell therapy for people with HPV-positive head & neck or cervical cancer. The treatment uses a patient's own immune cells, engineered to recognize and attack HPV-infected cancer cells. Some patients also received cells that produce an a…

This trial tested a new treatment for people with Epstein-Barr virus (EBV)-positive head and neck cancer that has spread or come back. The treatment uses specially engineered immune cells (TCR-T cells) that recognize EBV on cancer cells and also release a PD1 blocker to help them…

This study tested a new combination of two drugs (IO102-IO103 and pembrolizumab) as a first treatment for people with advanced lung, head/neck, or bladder cancer that has spread. A total of 63 patients took part. The goal was to see if the combo is safe and shrinks tumors. This i…

This study tested whether giving the immunotherapy drug durvalumab alongside radiation works better than the standard cetuximab plus radiation for people with advanced head and neck cancer who cannot take the usual chemotherapy drug cisplatin. A total of 196 adults took part. The…

This study tested a special smoking cessation program called ETIP in 19 patients with head and neck or lung cancer. The program included counseling, medication, and nicotine replacement to help patients cut down or quit smoking. Researchers also checked if reducing smoking change…

This study tested a new way to give radiation for head and neck cancer. Instead of treating the whole neck, doctors used artificial intelligence to focus radiation only on the cancer spots. 67 patients took part to see if this approach could reduce side effects without increasing…

This study tested a treatment plan for people with advanced head and neck cancer that cannot be removed by surgery. The plan combined the immunotherapy drug camrelizumab with chemotherapy and radiation. 39 adults took part. The goal was to see if the treatment could help control …

This study looked at whether a personalized blood test can find tiny bits of tumor DNA in 40 patients with advanced head and neck cancer. Researchers took blood samples before surgery, after surgery, and during 18 months of follow-up. The goal was to see if this test could help p…

This study collected tumor samples from 419 people with head and neck cancer to create a biobank. Researchers will use these samples in future genomic studies to find factors that predict how well a person will respond to treatment. The goal is to improve personalized outcome pre…

This study looked at whether a type of MRI called diffusion-weighted MRI (DW-MRI) can predict if head and neck cancer will come back after chemoradiotherapy. Researchers scanned 59 patients shortly after treatment and tracked them for up to a year. The goal was to see if changes …

This study tested a new blood test (liquid biopsy) to find cancer markers in 135 people with head and neck, lung, or skin cancer. The goal was to see if the blood test works as well as a standard tissue biopsy. The study did not provide treatment but aimed to improve how doctors …